GB201505305D0 - Novel Peptides and combination of peptides for use in immunotherapy against various tumors - Google Patents

Novel Peptides and combination of peptides for use in immunotherapy against various tumors

Info

Publication number
GB201505305D0
GB201505305D0 GBGB1505305.1A GB201505305A GB201505305D0 GB 201505305 D0 GB201505305 D0 GB 201505305D0 GB 201505305 A GB201505305 A GB 201505305A GB 201505305 D0 GB201505305 D0 GB 201505305D0
Authority
GB
United Kingdom
Prior art keywords
peptides
combination
against various
various tumors
immunotherapy against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1505305.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1505305.1A priority Critical patent/GB201505305D0/en
Publication of GB201505305D0 publication Critical patent/GB201505305D0/en
Priority to MA041805A priority patent/MA41805A/fr
Priority to MDE20180992T priority patent/MD3388075T2/ro
Priority to EP24164808.8A priority patent/EP4397676A3/en
Priority to CA3108776A priority patent/CA3108776A1/en
Priority to CA3111621A priority patent/CA3111621A1/en
Priority to SI201631731T priority patent/SI3388075T1/sl
Priority to SG10201806839PA priority patent/SG10201806839PA/en
Priority to CA3110160A priority patent/CA3110160A1/en
Priority to EA201791925A priority patent/EA039163B1/ru
Priority to RS20230622A priority patent/RS64397B1/sr
Priority to CR20200471A priority patent/CR20200471A/es
Priority to HK18105723.3A priority patent/HK1246181B/en
Priority to CA3111891A priority patent/CA3111891A1/en
Priority to CA3111739A priority patent/CA3111739A1/en
Priority to ES18174292T priority patent/ES2981540T3/es
Priority to KR1020217011039A priority patent/KR20210043752A/ko
Priority to SG10202001485UA priority patent/SG10202001485UA/en
Priority to DK16711659.9T priority patent/DK3273986T5/da
Priority to FIEP16711659.9T priority patent/FI3273986T3/fi
Priority to CA3111037A priority patent/CA3111037A1/en
Priority to KR1020227042333A priority patent/KR20220167337A/ko
Priority to CR20180422A priority patent/CR20180422A/es
Priority to IL298914A priority patent/IL298914A/en
Priority to PCT/EP2016/056557 priority patent/WO2016156202A1/en
Priority to MX2017012427A priority patent/MX2017012427A/es
Priority to MA40813A priority patent/MA40813A1/fr
Priority to EP18201235.1A priority patent/EP3456347B1/en
Priority to UAA201808809A priority patent/UA123953C2/uk
Priority to ES18201235T priority patent/ES2983924T3/es
Priority to CA3111194A priority patent/CA3111194A1/en
Priority to MA044999A priority patent/MA44999A/fr
Priority to MA043438A priority patent/MA43438A/fr
Priority to CA3112078A priority patent/CA3112078A1/en
Priority to CA3111096A priority patent/CA3111096A1/en
Priority to CA3111740A priority patent/CA3111740A1/en
Priority to PT181742511T priority patent/PT3388075T/pt
Priority to CA3111633A priority patent/CA3111633A1/en
Priority to UAA201708272A priority patent/UA124139C2/uk
Priority to CA3111077A priority patent/CA3111077A1/en
Priority to MYPI2017703099A priority patent/MY193703A/en
Priority to CN202110716733.5A priority patent/CN113480635A/zh
Priority to CA3111899A priority patent/CA3111899A1/en
Priority to CA3111059A priority patent/CA3111059A1/en
Priority to CA3110180A priority patent/CA3110180A1/en
Priority to CA3112084A priority patent/CA3112084A1/en
Priority to CA3110241A priority patent/CA3110241A1/en
Priority to DK18174251.1T priority patent/DK3388075T5/da
Priority to EP18174323.8A priority patent/EP3388078B1/en
Priority to PE2023002477A priority patent/PE20250413A1/es
Priority to HRP20230878TT priority patent/HRP20230878T8/hr
Priority to CA2980805A priority patent/CA2980805A1/en
Priority to ES16711659T priority patent/ES2970246T3/es
Priority to MA043440A priority patent/MA43440A/fr
Priority to KR1020187023154A priority patent/KR102251606B1/ko
Priority to AU2016239920A priority patent/AU2016239920B2/en
Priority to CA3111744A priority patent/CA3111744A1/en
Priority to HUE18174251A priority patent/HUE063627T2/hu
Priority to EP18174337.8A priority patent/EP3388079B1/en
Priority to ES18174354T priority patent/ES2986555T3/es
Priority to MA43435A priority patent/MA43435B1/fr
Priority to PL18174251.1T priority patent/PL3388075T3/pl
Priority to EP18174292.5A priority patent/EP3388076B1/en
Priority to EP18174251.1A priority patent/EP3388075B1/en
Priority to IL260877A priority patent/IL260877B2/en
Priority to BR112017017289A priority patent/BR112017017289A2/pt
Priority to IL254129A priority patent/IL254129B2/en
Priority to MA043437A priority patent/MA43437A/fr
Priority to IL301919A priority patent/IL301919A/en
Priority to EA201891699A priority patent/EA201891699A3/ru
Priority to CN201810930210.9A priority patent/CN109265517B/zh
Priority to JP2017549616A priority patent/JP6882985B2/ja
Priority to CN201680018847.XA priority patent/CN107531754B/zh
Priority to CA3111881A priority patent/CA3111881A1/en
Priority to EP16711659.9A priority patent/EP3273986B1/en
Priority to ES18174251T priority patent/ES2952959T3/es
Priority to FIEP18174251.1T priority patent/FI3388075T3/fi
Priority to CA3111648A priority patent/CA3111648A1/en
Priority to LTEP18174251.1T priority patent/LT3388075T/lt
Priority to NZ746513A priority patent/NZ746513A/en
Priority to MA043439A priority patent/MA43439A/fr
Priority to MA043436A priority patent/MA43436A/fr
Priority to CA3109693A priority patent/CA3109693A1/en
Priority to CA3111203A priority patent/CA3111203A1/en
Priority to KR1020177027189A priority patent/KR20170129787A/ko
Priority to EP18174312.1A priority patent/EP3388077A1/en
Priority to CA3110245A priority patent/CA3110245A1/en
Priority to PH1/2021/550850A priority patent/PH12021550850A1/en
Priority to EP18174354.3A priority patent/EP3388080B1/en
Priority to SG11201706681VA priority patent/SG11201706681VA/en
Priority to PE2017001462A priority patent/PE20171442A1/es
Priority to CA3109690A priority patent/CA3109690A1/en
Priority to ES18174337T priority patent/ES2991207T3/es
Priority to CR20200478A priority patent/CR20200478A/es
Priority to EA202191027A priority patent/EA202191027A3/ru
Priority to CA3111741A priority patent/CA3111741A1/en
Priority to MYPI2018702799A priority patent/MY200343A/en
Priority to TW109124266A priority patent/TW202043258A/zh
Priority to US15/082,978 priority patent/US20160279216A1/en
Priority to TW105109711A priority patent/TWI721971B/zh
Priority to US15/082,948 priority patent/US10081664B2/en
Priority to TW107128267A priority patent/TWI722311B/zh
Priority to US15/082,962 priority patent/US20160279215A1/en
Priority to US15/083,075 priority patent/US10000547B2/en
Priority to US15/083,106 priority patent/US9802997B2/en
Priority to US15/082,999 priority patent/US10081665B2/en
Priority to US15/082,986 priority patent/US9988432B2/en
Priority to TW112144237A priority patent/TW202413397A/zh
Priority to US15/082,933 priority patent/US9932384B2/en
Priority to US15/083,035 priority patent/US20160279218A1/en
Priority to US15/083,139 priority patent/US10336809B2/en
Priority to US15/082,967 priority patent/US10072063B2/en
Priority to US15/362,294 priority patent/US9982030B2/en
Priority to US15/362,274 priority patent/US9840548B2/en
Priority to US15/362,281 priority patent/US9862756B2/en
Priority to US15/638,678 priority patent/US20170305992A1/en
Priority to US15/638,667 priority patent/US9994628B2/en
Priority to US15/638,687 priority patent/US9951119B2/en
Priority to PH12017501650A priority patent/PH12017501650A1/en
Priority to CL2017002407A priority patent/CL2017002407A1/es
Priority to MX2021001622A priority patent/MX2021001622A/es
Priority to MX2018010875A priority patent/MX2018010875A/es
Priority to CONC2017/0009922A priority patent/CO2017009922A2/es
Priority to US15/789,567 priority patent/US10138288B2/en
Priority to US15/789,589 priority patent/US9982031B2/en
Priority to US15/789,683 priority patent/US10766944B2/en
Priority to US15/789,750 priority patent/US20180037628A1/en
Priority to US15/789,771 priority patent/US10370429B2/en
Priority to US15/789,731 priority patent/US10059755B2/en
Priority to US15/842,381 priority patent/US10005828B2/en
Priority to US15/847,825 priority patent/US10501522B2/en
Priority to US15/917,159 priority patent/US10202436B2/en
Priority to US15/919,984 priority patent/US10131703B2/en
Priority to US15/951,789 priority patent/US10183982B2/en
Priority to US15/953,128 priority patent/US10066003B1/en
Priority to US15/956,641 priority patent/US10106593B2/en
Priority to US15/956,638 priority patent/US10093715B2/en
Priority to US15/970,194 priority patent/US20180251517A1/en
Priority to US15/971,799 priority patent/US10106594B2/en
Priority to US15/976,621 priority patent/US10519215B2/en
Priority to US16/044,289 priority patent/US10155801B1/en
Priority to US16/044,266 priority patent/US20180327475A1/en
Priority to JP2018140996A priority patent/JP6742369B2/ja
Priority to US16/055,796 priority patent/US10934338B2/en
Priority to US16/126,663 priority patent/US10487131B2/en
Priority to AU2018232952A priority patent/AU2018232952C1/en
Priority to US16/152,122 priority patent/US10479823B2/en
Priority to US16/227,228 priority patent/US10450362B2/en
Priority to US16/227,257 priority patent/US20190119352A1/en
Priority to US16/293,749 priority patent/US20190185540A1/en
Priority to AU2019202561A priority patent/AU2019202561B2/en
Priority to US16/414,513 priority patent/US10745460B2/en
Priority to AU2019222976A priority patent/AU2019222976B2/en
Priority to US16/591,177 priority patent/US11702460B2/en
Priority to US16/591,083 priority patent/US11466072B2/en
Priority to US16/590,933 priority patent/US10723781B2/en
Priority to US16/681,363 priority patent/US11155597B2/en
Priority to CL2019003410A priority patent/CL2019003410A1/es
Priority to CL2019003409A priority patent/CL2019003409A1/es
Priority to CL2019003408A priority patent/CL2019003408A1/es
Priority to CL2019003405A priority patent/CL2019003405A1/es
Priority to CL2019003407A priority patent/CL2019003407A1/es
Priority to CL2019003406A priority patent/CL2019003406A1/es
Priority to CL2019003404A priority patent/CL2019003404A1/es
Priority to JP2020087423A priority patent/JP7217981B2/ja
Priority to JP2020091899A priority patent/JP2020188769A/ja
Priority to US16/900,542 priority patent/US10947293B2/en
Priority to US16/911,066 priority patent/US10947294B2/en
Priority to AU2020256298A priority patent/AU2020256298B2/en
Priority to US17/172,621 priority patent/US11897934B2/en
Priority to US17/172,577 priority patent/US11873329B2/en
Priority to US17/179,074 priority patent/US12060406B2/en
Priority to CL2021001565A priority patent/CL2021001565A1/es
Priority to CL2021001563A priority patent/CL2021001563A1/es
Priority to CL2021001564A priority patent/CL2021001564A1/es
Priority to AU2021204077A priority patent/AU2021204077B2/en
Priority to AU2021204080A priority patent/AU2021204080B2/en
Priority to AU2021204081A priority patent/AU2021204081B2/en
Priority to AU2021204076A priority patent/AU2021204076B2/en
Priority to AU2021204079A priority patent/AU2021204079B2/en
Priority to AU2021204078A priority patent/AU2021204078B2/en
Priority to AU2021204075A priority patent/AU2021204075B2/en
Priority to AU2021204074A priority patent/AU2021204074B2/en
Priority to US17/384,330 priority patent/US11407807B2/en
Priority to US17/390,503 priority patent/US11407808B2/en
Priority to US17/390,516 priority patent/US11365234B2/en
Priority to US17/396,377 priority patent/US11440947B2/en
Priority to US17/396,345 priority patent/US11365235B2/en
Priority to US17/396,323 priority patent/US12006349B2/en
Priority to US17/396,305 priority patent/US12018064B2/en
Priority to US17/401,720 priority patent/US11407809B2/en
Priority to CL2021002168A priority patent/CL2021002168A1/es
Priority to US17/459,150 priority patent/US11407810B2/en
Priority to US17/459,155 priority patent/US11434273B2/en
Priority to US17/492,111 priority patent/US11332512B2/en
Priority to US17/503,020 priority patent/US11459371B2/en
Priority to US17/514,743 priority patent/US11965013B2/en
Priority to US17/524,894 priority patent/US20220056103A1/en
Priority to CR20220115A priority patent/CR20220115A/es
Priority to US17/698,426 priority patent/US11434274B2/en
Priority to JP2022081847A priority patent/JP2022128606A/ja
Priority to ARP220102549A priority patent/AR127118A2/es
Priority to ARP220102547A priority patent/AR127116A2/es
Priority to ARP220102550A priority patent/AR127119A2/es
Priority to ARP220102548A priority patent/AR127117A2/es
Priority to US18/050,701 priority patent/US20230087025A1/en
Priority to US18/051,225 priority patent/US20230113246A1/en
Priority to US18/051,268 priority patent/US20230088740A1/en
Priority to US18/052,824 priority patent/US20230235016A1/en
Priority to US18/052,796 priority patent/US20230235015A1/en
Priority to US18/052,738 priority patent/US20230235014A1/en
Priority to US18/054,737 priority patent/US20230077903A1/en
Priority to US18/054,566 priority patent/US20230265158A1/en
Priority to US18/054,695 priority patent/US20230203127A1/en
Priority to US18/057,069 priority patent/US20230151076A1/en
Priority to AU2023201933A priority patent/AU2023201933A1/en
Priority to US18/315,183 priority patent/US20230348563A1/en
Priority to US18/647,837 priority patent/US20240294602A1/en
Priority to JP2024108608A priority patent/JP2024147612A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A61K39/001159—Matrix metalloproteinases [MMP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
GBGB1505305.1A 2015-03-27 2015-03-27 Novel Peptides and combination of peptides for use in immunotherapy against various tumors Ceased GB201505305D0 (en)

Priority Applications (219)

Application Number Priority Date Filing Date Title
GBGB1505305.1A GB201505305D0 (en) 2015-03-27 2015-03-27 Novel Peptides and combination of peptides for use in immunotherapy against various tumors
MA041805A MA41805A (fr) 2015-03-27 2016-03-23 Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
MDE20180992T MD3388075T2 (ro) 2015-03-27 2016-03-24 Noi peptide și combinații de peptide pentru utilizare în imunoterapia împotriva unor diverse tumori (SEQ ID 25 - MXRA5-003)
EP24164808.8A EP4397676A3 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3108776A CA3108776A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3111621A CA3111621A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
SI201631731T SI3388075T1 (sl) 2015-03-27 2016-03-24 Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti različnim tumorjem (SEQ ID 25 - MRAX5-003)
SG10201806839PA SG10201806839PA (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3110160A CA3110160A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
EA201791925A EA039163B1 (ru) 2015-03-27 2016-03-24 Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
RS20230622A RS64397B1 (sr) 2015-03-27 2016-03-24 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raznih tumora (seq id 25 - mrax5-003)
CR20200471A CR20200471A (es) 2015-03-27 2016-03-24 PÉPTIDOS Y COMBINACIÒN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Divisional 2017-0522)
HK18105723.3A HK1246181B (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3111891A CA3111891A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3111739A CA3111739A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
ES18174292T ES2981540T3 (es) 2015-03-27 2016-03-24 Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores (SEQ ID 274 - IGF-004)
KR1020217011039A KR20210043752A (ko) 2015-03-27 2016-03-24 다양한 종양에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
SG10202001485UA SG10202001485UA (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
DK16711659.9T DK3273986T5 (da) 2015-03-27 2016-03-24 Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
FIEP16711659.9T FI3273986T3 (fi) 2015-03-27 2016-03-24 Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
CA3111037A CA3111037A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
KR1020227042333A KR20220167337A (ko) 2015-03-27 2016-03-24 다양한 종양에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
CR20180422A CR20180422A (es) 2015-03-27 2016-03-24 PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (DIivisional 2017-0522)
IL298914A IL298914A (en) 2015-03-27 2016-03-24 Innovative peptides and peptide combinations for use in immunotherapy against various tumors
PCT/EP2016/056557 WO2016156202A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
MX2017012427A MX2017012427A (es) 2015-03-27 2016-03-24 Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
MA40813A MA40813A1 (fr) 2015-03-27 2016-03-24 Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
EP18201235.1A EP3456347B1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
UAA201808809A UA123953C2 (uk) 2015-03-27 2016-03-24 Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (мнс) людини і класу
ES18201235T ES2983924T3 (es) 2015-03-27 2016-03-24 Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
CA3111194A CA3111194A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
MA044999A MA44999A (fr) 2015-03-27 2016-03-24 Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre diverses tumeurs
MA043438A MA43438A (fr) 2015-03-27 2016-03-24 Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre diverses tumeurs (seq id 23 - mmp-002)
CA3112078A CA3112078A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3111096A CA3111096A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3111740A CA3111740A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
PT181742511T PT3388075T (pt) 2015-03-27 2016-03-24 Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores
CA3111633A CA3111633A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
UAA201708272A UA124139C2 (uk) 2015-03-27 2016-03-24 Пептид, який здатний зв'язуватися з молекулою головного комплексу гістосумісності (мнс) людини і класу
CA3111077A CA3111077A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
MYPI2017703099A MY193703A (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CN202110716733.5A CN113480635A (zh) 2015-03-27 2016-03-24 用于各种肿瘤免疫治疗的新型肽和肽组合物
CA3111899A CA3111899A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3111059A CA3111059A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3110180A CA3110180A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3112084A CA3112084A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3110241A CA3110241A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
DK18174251.1T DK3388075T5 (da) 2015-03-27 2016-03-24 Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
EP18174323.8A EP3388078B1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 23 - mmp-002)
PE2023002477A PE20250413A1 (es) 2015-03-27 2016-03-24 Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores
HRP20230878TT HRP20230878T8 (hr) 2015-03-27 2016-03-24 Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003)
CA2980805A CA2980805A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
ES16711659T ES2970246T3 (es) 2015-03-27 2016-03-24 Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
MA043440A MA43440A (fr) 2015-03-27 2016-03-24 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 243 - spc25-001)
KR1020187023154A KR102251606B1 (ko) 2015-03-27 2016-03-24 다양한 종양에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
AU2016239920A AU2016239920B2 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3111744A CA3111744A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
HUE18174251A HUE063627T2 (hu) 2015-03-27 2016-03-24 Új peptidek és peptidkombináció többféle tumor elleni immunterápiában
EP18174337.8A EP3388079B1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 253 - rad54b)
ES18174354T ES2986555T3 (es) 2015-03-27 2016-03-24 Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores (SEQ ID 243 – SPC25-001)
MA43435A MA43435B1 (fr) 2015-03-27 2016-03-24 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
PL18174251.1T PL3388075T3 (pl) 2015-03-27 2016-03-24 Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem różnych nowotworów
EP18174292.5A EP3388076B1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 274 - igf-004)
EP18174251.1A EP3388075B1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 25 - mrax5-003)
IL260877A IL260877B2 (en) 2015-03-27 2016-03-24 New peptides and a combination of peptides for use in immunotherapy against different types of tumors
BR112017017289A BR112017017289A2 (pt) 2015-03-27 2016-03-24 peptídeos e combinações de peptídeos para uso em imunoterapia contra diversos tumores
IL254129A IL254129B2 (en) 2015-03-27 2016-03-24 New peptides and a combination of peptides for use in immunotherapy against various tumors
MA043437A MA43437A (fr) 2015-03-27 2016-03-24 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 245 - magea4-003)
IL301919A IL301919A (en) 2015-03-27 2016-03-24 Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
EA201891699A EA201891699A3 (ru) 2015-03-27 2016-03-24 Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
CN201810930210.9A CN109265517B (zh) 2015-03-27 2016-03-24 用于各种肿瘤免疫治疗的肽和肽组合物
JP2017549616A JP6882985B2 (ja) 2015-03-27 2016-03-24 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ
CN201680018847.XA CN107531754B (zh) 2015-03-27 2016-03-24 用于各种肿瘤免疫治疗的新型肽和肽组合物
CA3111881A CA3111881A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
EP16711659.9A EP3273986B1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
ES18174251T ES2952959T3 (es) 2015-03-27 2016-03-24 Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra diversos tumores (SEQ ID N.º 25 - MXRA5-003)
FIEP18174251.1T FI3388075T3 (fi) 2015-03-27 2016-03-24 Uusia peptidejä ja peptidien yhdistelmiä käytettäviksi immunoterapiaan erilaisia syöpiä vastaan
CA3111648A CA3111648A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
LTEP18174251.1T LT3388075T (lt) 2015-03-27 2016-03-24 Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
NZ746513A NZ746513A (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
MA043439A MA43439A (fr) 2015-03-27 2016-03-24 Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre diverses tumeurs (seq id 253 - rad54b)
MA043436A MA43436A (fr) 2015-03-27 2016-03-24 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 274 - igf-004)
CA3109693A CA3109693A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CA3111203A CA3111203A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
KR1020177027189A KR20170129787A (ko) 2015-03-27 2016-03-24 다양한 종양에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
EP18174312.1A EP3388077A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 245 - magea4-003)
CA3110245A CA3110245A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
PH1/2021/550850A PH12021550850A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
EP18174354.3A EP3388080B1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 243 - spc25-001)
SG11201706681VA SG11201706681VA (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
PE2017001462A PE20171442A1 (es) 2015-03-27 2016-03-24 Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores
CA3109690A CA3109690A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
ES18174337T ES2991207T3 (es) 2015-03-27 2016-03-24 Péptidos novedosos y combinación de péptidos para su uso en inmunoterapia contra diversos tumores (SEQ ID 253 - Rad54b)
CR20200478A CR20200478A (es) 2015-03-27 2016-03-24 PÉPTIDOS Y COMBINACIONES DE PÉPTIDOS NOVEDOSOS PARA US USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Divisional 2017-0522)
EA202191027A EA202191027A3 (ru) 2015-03-27 2016-03-24 Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
CA3111741A CA3111741A1 (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
MYPI2018702799A MY200343A (en) 2015-03-27 2016-03-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
TW109124266A TW202043258A (zh) 2015-03-27 2016-03-28 用於各種腫瘤免疫治療的新型肽和肽複合物
US15/082,978 US20160279216A1 (en) 2015-03-27 2016-03-28 Novel peptides and combination of peptides for use in immunotherapy against various tumors
TW105109711A TWI721971B (zh) 2015-03-27 2016-03-28 用於各種腫瘤免疫治療的新型肽和肽複合物
US15/082,948 US10081664B2 (en) 2015-03-27 2016-03-28 Peptides and combination of peptides for use in immunotherapy against various tumors
TW107128267A TWI722311B (zh) 2015-03-27 2016-03-28 用於各種腫瘤免疫治療的新型肽和肽複合物
US15/082,962 US20160279215A1 (en) 2015-03-27 2016-03-28 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US15/083,075 US10000547B2 (en) 2015-03-27 2016-03-28 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/083,106 US9802997B2 (en) 2015-03-27 2016-03-28 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/082,999 US10081665B2 (en) 2015-03-27 2016-03-28 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/082,986 US9988432B2 (en) 2015-03-27 2016-03-28 Peptides and combination of peptides for use in immunotherapy against various tumors
TW112144237A TW202413397A (zh) 2015-03-27 2016-03-28 用於各種腫瘤免疫治療的新型肽和肽複合物
US15/082,933 US9932384B2 (en) 2015-03-27 2016-03-28 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/083,035 US20160279218A1 (en) 2015-03-27 2016-03-28 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US15/083,139 US10336809B2 (en) 2015-03-27 2016-03-28 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/082,967 US10072063B2 (en) 2015-03-27 2016-03-28 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/362,294 US9982030B2 (en) 2015-03-27 2016-11-28 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/362,274 US9840548B2 (en) 2015-03-27 2016-11-28 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/362,281 US9862756B2 (en) 2015-03-27 2016-11-28 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/638,678 US20170305992A1 (en) 2015-03-27 2017-06-30 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US15/638,667 US9994628B2 (en) 2015-03-27 2017-06-30 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/638,687 US9951119B2 (en) 2015-03-27 2017-06-30 Peptides and combination of peptides for use in immunotherapy against various tumors
PH12017501650A PH12017501650A1 (en) 2015-03-27 2017-09-11 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CL2017002407A CL2017002407A1 (es) 2015-03-27 2017-09-25 Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
MX2021001622A MX2021001622A (es) 2015-03-27 2017-09-27 Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
MX2018010875A MX2018010875A (es) 2015-03-27 2017-09-27 Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
CONC2017/0009922A CO2017009922A2 (es) 2015-03-27 2017-09-28 Péptidos y combinación de péptidos para inmunoterapia contra diversos tumores
US15/789,567 US10138288B2 (en) 2015-03-27 2017-10-20 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/789,589 US9982031B2 (en) 2015-03-27 2017-10-20 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/789,683 US10766944B2 (en) 2015-03-27 2017-10-20 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/789,750 US20180037628A1 (en) 2015-03-27 2017-10-20 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US15/789,771 US10370429B2 (en) 2015-03-27 2017-10-20 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/789,731 US10059755B2 (en) 2015-03-27 2017-10-20 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/842,381 US10005828B2 (en) 2015-03-27 2017-12-14 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/847,825 US10501522B2 (en) 2015-03-27 2017-12-19 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/917,159 US10202436B2 (en) 2015-03-27 2018-03-09 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/919,984 US10131703B2 (en) 2015-03-27 2018-03-13 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/951,789 US10183982B2 (en) 2015-03-27 2018-04-12 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/953,128 US10066003B1 (en) 2015-03-27 2018-04-13 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/956,641 US10106593B2 (en) 2015-03-27 2018-04-18 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/956,638 US10093715B2 (en) 2015-03-27 2018-04-18 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/970,194 US20180251517A1 (en) 2015-03-27 2018-05-03 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US15/971,799 US10106594B2 (en) 2015-03-27 2018-05-04 Peptides and combination of peptides for use in immunotherapy against various tumors
US15/976,621 US10519215B2 (en) 2015-03-27 2018-05-10 RELAXIN1 derived peptides for use in immunotherapy against various tumors
US16/044,289 US10155801B1 (en) 2015-03-27 2018-07-24 Peptides and combination of peptides for use in immunotherapy against various tumors
US16/044,266 US20180327475A1 (en) 2015-03-27 2018-07-24 Novel peptides and combination of peptides for use in immunotherapy against various tumors
JP2018140996A JP6742369B2 (ja) 2015-03-27 2018-07-27 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ
US16/055,796 US10934338B2 (en) 2015-03-27 2018-08-06 Peptides and combination of peptides for use in immunotherapy against various tumors
US16/126,663 US10487131B2 (en) 2015-03-27 2018-09-10 Peptides and combination of peptides for use in immunotherapy against various tumors
AU2018232952A AU2018232952C1 (en) 2015-03-27 2018-09-19 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US16/152,122 US10479823B2 (en) 2015-03-27 2018-10-04 Peptides and combination of peptides for use in immunotherapy against various tumors
US16/227,228 US10450362B2 (en) 2015-03-27 2018-12-20 Peptides and combination of peptides for use in immunotherapy against various tumors
US16/227,257 US20190119352A1 (en) 2015-03-27 2018-12-20 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US16/293,749 US20190185540A1 (en) 2015-03-27 2019-03-06 Novel peptides and combination of peptides for use in immunotherapy against various tumors
AU2019202561A AU2019202561B2 (en) 2015-03-27 2019-04-12 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US16/414,513 US10745460B2 (en) 2015-03-27 2019-05-16 Peptides and combination of peptides for use in immunotherapy against various tumors
AU2019222976A AU2019222976B2 (en) 2015-03-27 2019-09-02 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US16/591,177 US11702460B2 (en) 2015-03-27 2019-10-02 Peptides and combination of peptides for use in immunotherapy against various tumors
US16/591,083 US11466072B2 (en) 2015-03-27 2019-10-02 Peptides and combination of peptides for use in immunotherapy against various tumors
US16/590,933 US10723781B2 (en) 2015-03-27 2019-10-02 Peptides and combination of peptides for use in immunotherapy against various tumors
US16/681,363 US11155597B2 (en) 2015-03-27 2019-11-12 Relaxin1 derived peptides for use in immunotherapy
CL2019003410A CL2019003410A1 (es) 2015-03-27 2019-11-22 Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
CL2019003409A CL2019003409A1 (es) 2015-03-27 2019-11-22 Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
CL2019003408A CL2019003408A1 (es) 2015-03-27 2019-11-22 Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
CL2019003405A CL2019003405A1 (es) 2015-03-27 2019-11-22 Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
CL2019003407A CL2019003407A1 (es) 2015-03-27 2019-11-22 Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
CL2019003406A CL2019003406A1 (es) 2015-03-27 2019-11-22 Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
CL2019003404A CL2019003404A1 (es) 2015-03-27 2019-11-22 Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407)
JP2020087423A JP7217981B2 (ja) 2015-03-27 2020-05-19 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ
JP2020091899A JP2020188769A (ja) 2015-03-27 2020-05-27 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ
US16/900,542 US10947293B2 (en) 2015-03-27 2020-06-12 Peptides and combination of peptides for use in immunotherapy against various tumors
US16/911,066 US10947294B2 (en) 2015-03-27 2020-06-24 Peptides and combination of peptides for use in immunotherapy against various tumors
AU2020256298A AU2020256298B2 (en) 2015-03-27 2020-10-12 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US17/172,621 US11897934B2 (en) 2015-03-27 2021-02-10 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/172,577 US11873329B2 (en) 2015-03-27 2021-02-10 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/179,074 US12060406B2 (en) 2015-03-27 2021-02-18 Peptides and combination of peptides for use in immunotherapy against various tumors
CL2021001565A CL2021001565A1 (es) 2015-03-27 2021-06-15 Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores (divisional de la solicitud no. 201702407)
CL2021001563A CL2021001563A1 (es) 2015-03-27 2021-06-15 Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores (divisional de la solicitud no. 201702407)
CL2021001564A CL2021001564A1 (es) 2015-03-27 2021-06-15 Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores (divisional de la solicitud no. 201702407)
AU2021204077A AU2021204077B2 (en) 2015-03-27 2021-06-18 Novel peptides and combination of peptides for use in immunotherapy against various tumors
AU2021204080A AU2021204080B2 (en) 2015-03-27 2021-06-18 Novel peptides and combination of peptides for use in immunotherapy against various tumors
AU2021204081A AU2021204081B2 (en) 2015-03-27 2021-06-18 Novel peptides and combination of peptides for use in immunotherapy against various tumors
AU2021204076A AU2021204076B2 (en) 2015-03-27 2021-06-18 Novel peptides and combination of peptides for use in immunotherapy against various tumors
AU2021204079A AU2021204079B2 (en) 2015-03-27 2021-06-18 Novel peptides and combination of peptides for use in immunotherapy against various tumors
AU2021204078A AU2021204078B2 (en) 2015-03-27 2021-06-18 Novel peptides and combination of peptides for use in immunotherapy against various tumors
AU2021204075A AU2021204075B2 (en) 2015-03-27 2021-06-18 Novel peptides and combination of peptides for use in immunotherapy against various tumors
AU2021204074A AU2021204074B2 (en) 2015-03-27 2021-06-18 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US17/384,330 US11407807B2 (en) 2015-03-27 2021-07-23 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/390,503 US11407808B2 (en) 2015-03-27 2021-07-30 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/390,516 US11365234B2 (en) 2015-03-27 2021-07-30 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/396,377 US11440947B2 (en) 2015-03-27 2021-08-06 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/396,345 US11365235B2 (en) 2015-03-27 2021-08-06 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/396,323 US12006349B2 (en) 2015-03-27 2021-08-06 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/396,305 US12018064B2 (en) 2015-03-27 2021-08-06 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/401,720 US11407809B2 (en) 2015-03-27 2021-08-13 Peptides and combination of peptides for use in immunotherapy against various tumors
CL2021002168A CL2021002168A1 (es) 2015-03-27 2021-08-16 Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407).
US17/459,150 US11407810B2 (en) 2015-03-27 2021-08-27 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/459,155 US11434273B2 (en) 2015-03-27 2021-08-27 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/492,111 US11332512B2 (en) 2015-03-27 2021-10-01 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/503,020 US11459371B2 (en) 2015-03-27 2021-10-15 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/514,743 US11965013B2 (en) 2015-03-27 2021-10-29 Peptides and combination of peptides for use in immunotherapy against various tumors
US17/524,894 US20220056103A1 (en) 2015-03-27 2021-11-12 Novel peptides and combination of peptides for use in immunotherapy against various tumors
CR20220115A CR20220115A (es) 2015-03-27 2022-03-16 PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Div. 2017-522)
US17/698,426 US11434274B2 (en) 2015-03-27 2022-03-18 Peptides and combination of peptides for use in immunotherapy against various tumors
JP2022081847A JP2022128606A (ja) 2015-03-27 2022-05-18 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ
ARP220102549A AR127118A2 (es) 2015-03-27 2022-09-21 Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
ARP220102547A AR127116A2 (es) 2015-03-27 2022-09-21 Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
ARP220102550A AR127119A2 (es) 2015-03-27 2022-09-21 Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
ARP220102548A AR127117A2 (es) 2015-03-27 2022-09-21 Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
US18/050,701 US20230087025A1 (en) 2015-03-27 2022-10-28 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US18/051,225 US20230113246A1 (en) 2015-03-27 2022-10-31 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US18/051,268 US20230088740A1 (en) 2015-03-27 2022-10-31 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US18/052,824 US20230235016A1 (en) 2015-03-27 2022-11-04 Peptides and combination of peptides for use in immunotherapy against various tumors
US18/052,796 US20230235015A1 (en) 2015-03-27 2022-11-04 Peptides and combination of peptides for use in immunotherapy against various tumors
US18/052,738 US20230235014A1 (en) 2015-03-27 2022-11-04 Peptides and combination of peptides for use in immunotherapy against various tumors
US18/054,737 US20230077903A1 (en) 2015-03-27 2022-11-11 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US18/054,566 US20230265158A1 (en) 2015-03-27 2022-11-11 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US18/054,695 US20230203127A1 (en) 2015-03-27 2022-11-11 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US18/057,069 US20230151076A1 (en) 2015-03-27 2022-11-18 Novel peptides and combination of peptides for use in immunotherapy against various tumors
AU2023201933A AU2023201933A1 (en) 2015-03-27 2023-03-30 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US18/315,183 US20230348563A1 (en) 2015-03-27 2023-05-10 Novel peptides and combination of peptides for use in immunotherapy against various tumors
US18/647,837 US20240294602A1 (en) 2015-03-27 2024-04-26 Novel peptides and combination of peptides for use in immunotherapy against various tumors
JP2024108608A JP2024147612A (ja) 2015-03-27 2024-07-05 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1505305.1A GB201505305D0 (en) 2015-03-27 2015-03-27 Novel Peptides and combination of peptides for use in immunotherapy against various tumors

Publications (1)

Publication Number Publication Date
GB201505305D0 true GB201505305D0 (en) 2015-05-13

Family

ID=53178247

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1505305.1A Ceased GB201505305D0 (en) 2015-03-27 2015-03-27 Novel Peptides and combination of peptides for use in immunotherapy against various tumors

Country Status (19)

Country Link
US (52) US10000547B2 (enExample)
EP (8) EP3456347B1 (enExample)
JP (1) JP6882985B2 (enExample)
KR (3) KR20210043752A (enExample)
CN (2) CN107531754B (enExample)
AR (4) AR127116A2 (enExample)
AU (13) AU2016239920B2 (enExample)
BR (1) BR112017017289A2 (enExample)
CA (26) CA3111881A1 (enExample)
CR (3) CR20200478A (enExample)
EA (3) EA039163B1 (enExample)
GB (1) GB201505305D0 (enExample)
MA (9) MA41805A (enExample)
MX (1) MX2017012427A (enExample)
PE (1) PE20171442A1 (enExample)
SG (3) SG10202001485UA (enExample)
TW (3) TWI721971B (enExample)
UA (2) UA123953C2 (enExample)
WO (1) WO2016156202A1 (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
RS64397B1 (sr) 2015-03-27 2023-08-31 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raznih tumora (seq id 25 - mrax5-003)
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
KR20240161207A (ko) 2015-05-06 2024-11-12 이매틱스 바이오테크놀로지스 게엠베하 결장직장 암종(crc) 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드와 이의 골격의 조합
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520545D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CA3008641A1 (en) 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
ZA201900664B (en) 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
DE102016123859B3 (de) * 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
CN110637028B (zh) * 2016-12-29 2024-10-22 得克萨斯州大学系统董事会 Hla限制性vcx/y肽和t细胞受体及其用途
JP7303750B2 (ja) * 2017-01-24 2023-07-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物
CR20210130A (es) * 2017-01-27 2021-03-31 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de càncer (divisional exp. 2019-388)
WO2018138257A1 (en) * 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2018145020A1 (en) 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
AU2018228719B2 (en) 2017-02-28 2023-03-30 Affimed Gmbh Tandem diabody for CD16A-directed NK-cell engagement
EP3366704A1 (en) 2017-02-28 2018-08-29 Affimed GmbH Antibodies specific for mmp1/hla-a2 complex
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
GB201704128D0 (en) * 2017-03-15 2017-04-26 Univ Swansea Method and apparatus for use in diagnosis and monitoring of colorectal cancer
US11427614B2 (en) 2017-04-10 2022-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
MA49122A (fr) * 2017-04-10 2021-03-24 Immatics Biotechnologies Gmbh Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
KR20250007011A (ko) 2017-07-07 2025-01-13 이매틱스 바이오테크놀로지스 게엠베하 Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
LT3652215T (lt) 2017-07-14 2021-05-25 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
WO2019067887A1 (en) * 2017-09-29 2019-04-04 Spyryx Biosciences, Inc. ENAC INHIBITOR PEPTIDES AND USES THEREOF
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
EP4219543A1 (en) * 2017-11-06 2023-08-02 Immatics Biotechnologies GmbH Novel engineered t cell receptors and immune therapy using the same
DE102017125888A1 (de) * 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
US11464800B2 (en) 2018-02-09 2022-10-11 Immatics US, Inc. Methods for manufacturing T cells
JP6857930B2 (ja) * 2018-02-15 2021-04-14 国立大学法人旭川医科大学 がん抗原ペプチド
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
JP2021517810A (ja) 2018-03-12 2021-07-29 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 養子免疫療法における腫瘍自己抗原の使用のための方法および組成物
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
EP3545967A1 (en) * 2018-03-28 2019-10-02 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer immunization platform
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CN112292037B (zh) 2018-06-19 2024-03-22 帝斯曼知识产权资产管理有限公司 脂解酶变体
AU2019288765A1 (en) * 2018-06-22 2021-01-07 Merck Patent Gmbh Dosing regimens for targeted TGF-β inhibition for use in treating biliary tract cancer
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) * 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) * 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
JP2022516703A (ja) 2019-01-06 2022-03-02 セカンド ゲノム インコーポレイテッド 免疫療法のための微生物由来のペプチドおよびタンパク質
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
US20220211832A1 (en) * 2019-05-15 2022-07-07 Genocea Biosciences, Inc. Treatment methods
PE20220164A1 (es) 2019-05-27 2022-01-28 Immatics Us Inc Vectores viricos y uso de los mismos en terapias celulares adoptivas
PH12021553042A1 (en) 2019-06-06 2023-09-11 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN110567861B (zh) * 2019-09-09 2021-12-21 浙江普罗亭健康科技有限公司 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法
CN110804643B (zh) * 2019-10-29 2022-06-21 同济大学 一种体外评价卡介苗对中性粒细胞活性影响的方法
WO2021113328A1 (en) 2019-12-03 2021-06-10 Neuvogen, Inc. Tumor cell vaccines
BR112022016909A2 (pt) 2020-02-24 2022-12-06 Immatics Us Inc Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022047325A1 (en) * 2020-08-31 2022-03-03 The Trustees Of Columbia University In The City Of New York Targeting of tgm4 to treat prostate cancer
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US11891427B2 (en) 2020-09-29 2024-02-06 Immatics Biotechnologies Gmbh Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
WO2022125874A2 (en) * 2020-12-11 2022-06-16 Berkeley Lights, Inc. Methods for identification of exchangeable mhc binding peptides and methods of use thereof
CN117083081A (zh) * 2020-12-14 2023-11-17 百欧恩泰美国公司 用于癌症免疫疗法的组织特异性抗原
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
AU2022233285A1 (en) 2021-03-09 2023-10-19 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
JP2024511950A (ja) * 2021-03-12 2024-03-18 ティー－キュア バイオサイエンス，インコーポレイテッド Ｔｃｒ－ｔ療法に対する腫瘍細胞の感受性を広げるための腫瘍におけるｈｌａハプロタイプ発現の多様性の増強方法
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
WO2022256700A1 (en) * 2021-06-04 2022-12-08 Second Genome, Inc. Peptides for immunotherapy
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
EP4392441A1 (en) 2021-08-24 2024-07-03 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
CN115785204B (zh) * 2022-06-10 2024-02-13 河北博海生物工程开发有限公司 肺癌特异性分子靶标08及其用途
CN120202015A (zh) 2022-09-14 2025-06-24 Cdr-生物科技股份有限公司 Mage-a4肽双重t细胞衔接子
CN115747307A (zh) * 2022-11-03 2023-03-07 郑州大学 一种用于富集检测复发肿瘤细胞的dna水凝胶的制备方法及其应用
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025124536A1 (zh) * 2023-12-15 2025-06-19 江苏康缘药业股份有限公司 趋化因子受体8拮抗多肽化合物、组合物、试剂盒及用途
CN118166098B (zh) * 2024-02-05 2024-09-10 北京大学深圳医院 检测magea4-as1的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用
CN120718855A (zh) * 2025-09-03 2025-09-30 天津医科大学总医院 一种具有高淋巴结转移潜力的中国人肺大细胞神经内分泌癌细胞系及应用

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211999B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4493795A (en) * 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
JPH07108224B2 (ja) 1985-11-07 1995-11-22 重三 鵜高 バチルス・ブレビスを用いる遺伝子の発現方法
US4772557A (en) * 1985-11-12 1988-09-20 Washington University DNA clone of human skin fibroblast collagenase enzyme
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
AU6012696A (en) 1995-06-14 1997-01-15 Aberdeen University Prognostic and therapeutic system for cancer
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
US6815531B1 (en) * 1996-06-07 2004-11-09 Kyogo Itoh Tumor antigen proteins, genes thereof, and tumor antigen peptides
AU4086397A (en) 1996-09-06 1998-03-26 Centocor Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US7105488B1 (en) * 1998-02-27 2006-09-12 The United States Of America As Represented By The Department Of Health And Human Services G protein-coupled receptor antagonists
WO1999043711A1 (en) 1998-02-27 1999-09-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services G protein-coupled receptor antagonists
US6255055B1 (en) 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030236209A1 (en) * 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
AU2001213184A1 (en) 1998-09-28 2002-05-06 Bio Polymer Products Of Sweden Ab A process of producing polyphenolic adhesive proteins and proteins produced in accordance with the process
US20070020327A1 (en) 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US7259253B2 (en) * 1999-05-14 2007-08-21 Quark Biotech, Inc. Genes associated with mechanical stress, expression products therefrom, and uses thereof
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
US20020123095A1 (en) 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
US20040142361A1 (en) 1999-11-30 2004-07-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
JP2003517310A (ja) * 1999-12-10 2003-05-27 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｍａｇｅ２／３に対する細胞性免疫応答の誘導
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
US20030050456A1 (en) 2000-02-24 2003-03-13 Gabriel Vogeli Novel G protein-coupled receptors
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
US7094890B1 (en) 2000-03-10 2006-08-22 Novartis Ag Arthritis-associated protein
US20030165831A1 (en) 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030073622A1 (en) 2000-06-07 2003-04-17 Kumud Majumder Novel proteins and nucleic acids encoding same
AU2001268361A1 (en) 2000-07-07 2002-01-21 Saint Louis University Method of modulating expression of ldl-receptor-related protein and uses thereof
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20070014801A1 (en) 2001-01-24 2007-01-18 Gish Kurt C Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP1911461B1 (en) 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
AU2001286560A1 (en) 2000-10-20 2002-05-06 Applera Corporation Estrogen receptor alpha variants and methods of detection thereof
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040053822A1 (en) 2000-12-11 2004-03-18 John Fikes Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
WO2002050277A2 (en) 2000-12-21 2002-06-27 Curagen Corporation Protein and nucleic acids encoding same
WO2002068649A2 (en) 2001-01-31 2002-09-06 Curagen Corporation Proteins and nucleic acids encoding same
US20050069976A1 (en) 2001-02-14 2005-03-31 Peter Lind Protein-coupled receptor
EP1368475A4 (en) * 2001-03-15 2004-10-20 Nuvelo Inc NEW NUCLEIC ACIDS AND NEW POLYPEPTIDES
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
US20030077664A1 (en) 2001-04-18 2003-04-24 Yi Zhao Methods of screening for compounds that modulate hormone receptor activity
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
EP1446757A2 (en) 2001-05-30 2004-08-18 Biomedical Center In silico screening for phenotype-associated expressed sequences
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20030068636A1 (en) 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2003000928A2 (en) 2001-06-25 2003-01-03 Buadbo Aps Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
JP2003088388A (ja) 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2002343417A1 (en) 2001-09-24 2003-04-14 Nuvelo Novel nucleic acids and polypeptides
JP2003135075A (ja) 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
US20030148410A1 (en) 2001-12-10 2003-08-07 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US6689431B2 (en) 2001-12-12 2004-02-10 Eastman Kodak Company Ink jet recording element
AU2003207738A1 (en) 2002-01-29 2003-09-02 Quark Biotech, Inc. Islr gene and its association with osteoarthritis and other bone and cartilage disorders, expression products derived therefrom, and uses thereof
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004014867A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
JP2006516089A (ja) 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US7482117B2 (en) 2002-12-20 2009-01-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
EP1590485A2 (en) 2003-01-30 2005-11-02 Applera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
DE10309729A1 (de) 2003-02-26 2004-09-16 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Harnblasenkarzinomen
WO2004081186A2 (en) 2003-03-10 2004-09-23 Applera Corporation Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof
CN1331885C (zh) * 2003-05-15 2007-08-15 北京大学 肿瘤抗原蛋白及抗原肽在作为肿瘤－睾丸抗原、制备治疗肝癌/肺癌药物中的应用
EP1633866A1 (en) 2003-06-18 2006-03-15 Direvo Biotech AG New biological entities and the pharmaceutical or diagnostic use thereof
ATE526399T1 (de) 2003-06-18 2011-10-15 Bayer Pharma AG Neue biologische einheiten und deren verwendung
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
US7667001B1 (en) 2004-01-27 2010-02-23 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
US7569662B2 (en) 2004-01-27 2009-08-04 Compugen Ltd Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
US7368548B2 (en) 2004-01-27 2008-05-06 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer
WO2005072053A2 (en) 2004-01-27 2005-08-11 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer
WO2005087811A2 (en) * 2004-03-10 2005-09-22 Creighton University Estrogen receptors and methods of use
WO2005114221A2 (en) * 2004-05-21 2005-12-01 The Institute For Systems Biology Compositions and methods for quantification of serum glycoproteins
WO2006088483A2 (en) * 2004-06-16 2006-08-24 Trustees Of Dartmouth College Compositions and methods for inhibiting the synthesis or expression of mmp-1
WO2006037993A2 (en) 2004-10-02 2006-04-13 Auvation Limited Cancer markers
DE102005059937A1 (de) 2004-12-21 2006-07-13 Continental Teves Ag & Co. Ohg Verfahren zum Betrieb einer hydraulischen Bremsanlage für Kraftfahrzeuge
WO2006067198A2 (en) 2004-12-22 2006-06-29 Direvo Biotech Ag Targeted use of engineered enzymes
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
RU2007135030A (ru) * 2005-02-24 2009-03-27 Симайнз, Инк. (Us) Композиции и способы классификации биологических образцов
US8404803B2 (en) 2005-03-31 2013-03-26 Chugai Seiyaku Kabushiki Kaisha Cancer-associated antigen analogue peptides and uses thereof
US7842467B1 (en) 2005-05-12 2010-11-30 Celera Corporation Breast disease targets and uses thereof
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
ES2330013T3 (es) 2005-09-05 2009-12-03 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas.
ATE461215T1 (de) * 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
CA2623531C (en) * 2005-10-07 2013-12-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Matrix metalloproteinase 11 vaccine
US20070099251A1 (en) * 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer
WO2008016356A2 (en) 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
CA2674209A1 (en) * 2006-12-29 2008-07-10 Ipsen Pharma S.A.S. Glp-1 pharmaceutical compositions
US7589662B1 (en) 2007-06-20 2009-09-15 The United States Of America As Represented By The Secretary Of The Navy Synthetic aperture radar systems and methods
HUE027057T2 (en) 2007-07-27 2016-08-29 Immatics Biotechnologies Gmbh New immunogenic epitope for immunotherapy
DK2186889T3 (en) 2007-08-20 2015-06-08 Oncotherapy Science Inc CDCA1 PEPTID AND PHARMACEUTICAL COMPOSITION, INCLUDING THIS
WO2009036246A2 (en) * 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
WO2009102909A2 (en) * 2008-02-15 2009-08-20 Board Of Regents, The University Of Texas System Anti-cancer vaccines
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
AU2009234444A1 (en) * 2008-04-11 2009-10-15 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
HUE024541T2 (hu) * 2008-05-14 2016-01-28 Immatics Biotechnologies Gmbh Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
JP2012506551A (ja) 2008-10-22 2012-03-15 バイオマーカー デザイン フォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨または軟骨障害の検出および診断のための方法
KR101032860B1 (ko) 2008-10-22 2011-05-06 한국식품연구원 췌장 조직 특이적 유전자 ｍｍｐ1
CN102307595A (zh) * 2009-02-10 2012-01-04 盛诺基医药科技有限公司 治疗雌激素受体相关疾病的抗体及方法
WO2010102157A1 (en) * 2009-03-04 2010-09-10 The Regents Of The University Of California Molecular predictors of biological response to a cenpe inhibitor in cancer
JP5649589B2 (ja) 2009-03-06 2015-01-07 ハロザイム インコーポレイテッド マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用
US20120077696A1 (en) 2009-03-15 2012-03-29 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
US8741581B2 (en) * 2009-04-27 2014-06-03 Technion Research And Development Foundation Ltd. Markers for cancer detection
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US20130011496A1 (en) 2009-11-25 2013-01-10 Ludwig Institute For Cancer Research Ltd. Cancer testis antigens as biomarkers in non-small cell lung cancer
EP2531217A4 (en) * 2010-02-04 2013-11-27 Gilead Biologics Inc ANTIBODIES THAT BIND TO LOXL2 (LYSYL OXIDASE-LIKE 2) AND METHODS OF USE THEREOF
EP3572091B1 (en) * 2010-08-17 2023-12-13 Ambrx, Inc. Modified relaxin polypeptides and their uses
JP6021021B2 (ja) 2010-11-05 2016-11-02 国立大学法人京都大学 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法
WO2012068210A1 (en) 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012094744A1 (en) 2011-01-11 2012-07-19 University Health Network Prognostic signature for oral squamous cell carcinoma
US20130064901A1 (en) * 2011-04-18 2013-03-14 Agency For Science, Technology And Research Gene expression profiling for classifying and treating gastric cancer
US20120302569A1 (en) 2011-05-25 2012-11-29 Paul Francis Jackson Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
US20120302573A1 (en) 2011-05-25 2012-11-29 Paul Francis Jackson Methods of inhibiting pro matrix metalloproteinase activation
EP2751561A4 (en) 2011-08-31 2015-08-12 Oncocyte Corp METHOD AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF COLORECTAL CARCINOMA
WO2013036754A2 (en) * 2011-09-09 2013-03-14 The Wistar Institute Of Anatomy And Biology Methods and compositions for diagnosis of ovarian cancer
US9091651B2 (en) 2011-12-21 2015-07-28 Integrated Diagnostics, Inc. Selected reaction monitoring assays
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
JP6168497B2 (ja) 2012-03-30 2017-07-26 国立大学法人 岡山大学 抗体検出用試薬の製造方法、及びその用途
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
EP2669378A1 (en) 2012-05-31 2013-12-04 Helmut Hanenberg Cytochrome P450 suicide gene system
MX367279B (es) * 2012-09-14 2019-08-13 Us Health Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
US20160000893A1 (en) 2012-12-13 2016-01-07 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
TWI636065B (zh) * 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
RS64397B1 (sr) 2015-03-27 2023-08-31 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raznih tumora (seq id 25 - mrax5-003)
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
DE102017006829B3 (de) 2017-07-19 2018-09-06 Daimler Ag Regalsystem
WO2019133853A1 (en) 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
AU2019275072A1 (en) 2018-05-23 2021-01-21 Seattle Project Corp. Shared antigens
CN113939310A (zh) 2019-03-30 2022-01-14 百欧恩泰美国公司 用于制备t细胞组合物的组合物和方法及其用途

Also Published As

Publication number Publication date
EP3388080B1 (en) 2024-07-03
US20180208641A1 (en) 2018-07-26
US10336809B2 (en) 2019-07-02
US20200087378A1 (en) 2020-03-19
AU2021204077B2 (en) 2023-02-02
AU2018232952C1 (en) 2020-10-29
AU2021204078A1 (en) 2021-07-15
AU2021204075B2 (en) 2023-02-02
US20180340019A1 (en) 2018-11-29
SG10202001485UA (en) 2020-04-29
AU2021204074B2 (en) 2023-02-02
US20160279217A1 (en) 2016-09-29
CA3110160A1 (en) 2016-10-06
CN107531754A (zh) 2018-01-02
US10723781B2 (en) 2020-07-28
US9988432B2 (en) 2018-06-05
MA43439A (fr) 2018-10-17
US10766944B2 (en) 2020-09-08
US9982031B2 (en) 2018-05-29
MA43437A (fr) 2018-10-17
US20180237493A1 (en) 2018-08-23
US20210188943A1 (en) 2021-06-24
CA3111741A1 (en) 2016-10-06
US9994628B2 (en) 2018-06-12
MA43435A (fr) 2018-10-17
US11897934B2 (en) 2024-02-13
AU2021204074A1 (en) 2021-07-15
AU2021204075A1 (en) 2021-07-15
US10487131B2 (en) 2019-11-26
US20190119351A1 (en) 2019-04-25
AU2021204076A1 (en) 2021-07-15
MX2017012427A (es) 2018-01-11
US20180230195A1 (en) 2018-08-16
US20180346548A1 (en) 2018-12-06
CA3111621A1 (en) 2016-10-06
US20200308250A1 (en) 2020-10-01
AU2021204081B2 (en) 2023-04-13
AU2016239920B2 (en) 2019-07-04
US20180100005A1 (en) 2018-04-12
US20180251518A1 (en) 2018-09-06
CR20200478A (es) 2021-01-20
KR20170129787A (ko) 2017-11-27
EP3388080A1 (en) 2018-10-17
US10519215B2 (en) 2019-12-31
TW202043258A (zh) 2020-12-01
US20170145073A1 (en) 2017-05-25
CA3111059A1 (en) 2016-10-06
US10005828B2 (en) 2018-06-26
US9982030B2 (en) 2018-05-29
AR127119A2 (es) 2023-12-20
US20190185540A1 (en) 2019-06-20
AU2021204079A1 (en) 2021-07-15
CA3110245A1 (en) 2016-10-06
CN113480635A (zh) 2021-10-08
US20160279215A1 (en) 2016-09-29
US20190023762A1 (en) 2019-01-24
AR127118A2 (es) 2023-12-20
AU2021204078B2 (en) 2023-02-02
US20160279214A1 (en) 2016-09-29
EP3388077A1 (en) 2018-10-17
UA124139C2 (uk) 2021-07-28
EA202191027A2 (ru) 2021-07-30
MA41805A (fr) 2018-01-30
WO2016156202A1 (en) 2016-10-06
EP3273986A1 (en) 2018-01-31
JP6882985B2 (ja) 2021-06-02
AU2019222976A1 (en) 2019-09-26
CA3109690A1 (en) 2016-10-06
TWI722311B (zh) 2021-03-21
US20190002524A1 (en) 2019-01-03
CA3109693A1 (en) 2016-10-06
EP3456347A1 (en) 2019-03-20
AU2021204077A1 (en) 2021-07-15
AU2018232952A1 (en) 2018-10-11
KR102251606B1 (ko) 2021-05-12
EP3273986B1 (en) 2023-11-22
US20160279216A1 (en) 2016-09-29
US10106594B2 (en) 2018-10-23
TW201700496A (zh) 2017-01-01
US11466072B2 (en) 2022-10-11
KR20210043752A (ko) 2021-04-21
CA3111633A1 (en) 2016-10-06
MA44999A (fr) 2019-03-20
US20180208640A1 (en) 2018-07-26
CA3110241A1 (en) 2016-10-06
CA3112078A1 (en) 2016-10-06
US10183982B2 (en) 2019-01-22
US9840548B2 (en) 2017-12-12
CA3111037A1 (en) 2016-10-06
CR20180422A (es) 2018-11-16
AU2019222976B2 (en) 2021-03-18
US20160280752A1 (en) 2016-09-29
US20180037628A1 (en) 2018-02-08
US20170145072A1 (en) 2017-05-25
US20180094043A1 (en) 2018-04-05
US9932384B2 (en) 2018-04-03
PE20171442A1 (es) 2017-09-29
EA201791925A1 (ru) 2018-02-28
CR20200471A (es) 2021-01-26
US20200040060A1 (en) 2020-02-06
US10000547B2 (en) 2018-06-19
CN107531754B (zh) 2024-11-15
MA43440A (fr) 2018-10-17
US10450362B2 (en) 2019-10-22
US10081665B2 (en) 2018-09-25
AR127116A2 (es) 2023-12-20
US20180141993A1 (en) 2018-05-24
US9951119B2 (en) 2018-04-24
AU2020256298B2 (en) 2022-07-14
US10106593B2 (en) 2018-10-23
CA3111740A1 (en) 2016-10-06
US20180030113A1 (en) 2018-02-01
US11155597B2 (en) 2021-10-26
AU2021204076B2 (en) 2022-12-22
US20170305992A1 (en) 2017-10-26
US20160280758A1 (en) 2016-09-29
EP3388078A1 (en) 2018-10-17
EP3388075B1 (en) 2023-05-24
US10081664B2 (en) 2018-09-25
CA3111194A1 (en) 2016-10-06
US20160280757A1 (en) 2016-09-29
US20210188944A1 (en) 2021-06-24
AU2021204081A1 (en) 2021-07-15
AU2021204080B2 (en) 2023-02-02
US20180237494A1 (en) 2018-08-23
US11702460B2 (en) 2023-07-18
MA43436A (fr) 2018-10-17
US20160280760A1 (en) 2016-09-29
US20200325206A1 (en) 2020-10-15
US10072063B2 (en) 2018-09-11
EP3456347B1 (en) 2024-07-03
CA2980805A1 (en) 2016-10-06
TWI721971B (zh) 2021-03-21
US20170158750A1 (en) 2017-06-08
EP3388079B1 (en) 2024-05-29
US20160280738A1 (en) 2016-09-29
US20200024325A1 (en) 2020-01-23
US10947293B2 (en) 2021-03-16
CA3111203A1 (en) 2016-10-06
EA201891699A2 (ru) 2018-12-28
US10947294B2 (en) 2021-03-16
US20190119352A1 (en) 2019-04-25
AU2021204079B2 (en) 2023-02-02
US10934338B2 (en) 2021-03-02
AU2016239920A1 (en) 2017-08-24
CA3111881A1 (en) 2016-10-06
EP3388076B1 (en) 2024-05-29
SG11201706681VA (en) 2017-10-30
TW201902917A (zh) 2019-01-16
MA43435B1 (fr) 2023-08-31
US20170313760A1 (en) 2017-11-02
CA3111096A1 (en) 2016-10-06
EP3388078B1 (en) 2024-05-29
MA40813A1 (fr) 2018-02-28
US20180037626A1 (en) 2018-02-08
US20160279218A1 (en) 2016-09-29
SG10201806839PA (en) 2018-09-27
CA3111891A1 (en) 2016-10-06
CA3111648A1 (en) 2016-10-06
EA039163B1 (ru) 2021-12-13
KR20180093124A (ko) 2018-08-20
US9802997B2 (en) 2017-10-31
US10093715B2 (en) 2018-10-09
US20180327475A1 (en) 2018-11-15
UA123953C2 (uk) 2021-06-30
US10059755B2 (en) 2018-08-28
CA3112084A1 (en) 2016-10-06
CA3111744A1 (en) 2016-10-06
AU2019202561B2 (en) 2020-07-23
EA202191027A3 (ru) 2021-12-31
JP2018519243A (ja) 2018-07-19
US9862756B2 (en) 2018-01-09
US10202436B2 (en) 2019-02-12
AU2019202561A1 (en) 2019-05-02
US11873329B2 (en) 2024-01-16
CA3111739A1 (en) 2016-10-06
AU2020256298A1 (en) 2020-11-05
US20210179691A1 (en) 2021-06-17
AU2018232952B2 (en) 2020-07-16
US20200031899A1 (en) 2020-01-30
US20180037627A1 (en) 2018-02-08
US10479823B2 (en) 2019-11-19
CA3108776A1 (en) 2016-10-06
CA3111899A1 (en) 2016-10-06
CA3111077A1 (en) 2016-10-06
CA3110180A1 (en) 2016-10-06
EA201891699A3 (ru) 2019-04-30
US20160280759A1 (en) 2016-09-29
US20180251517A1 (en) 2018-09-06
AR127117A2 (es) 2023-12-20
US10066003B1 (en) 2018-09-04
MA43438A (fr) 2018-10-17
US12060406B2 (en) 2024-08-13
US10131703B2 (en) 2018-11-20
US20220009995A1 (en) 2022-01-13
EP3388079A1 (en) 2018-10-17
US10370429B2 (en) 2019-08-06
EP3388076A1 (en) 2018-10-17
EP3388075A1 (en) 2018-10-17
US20180230194A1 (en) 2018-08-16
US10138288B2 (en) 2018-11-27
US20180037629A1 (en) 2018-02-08
US10501522B2 (en) 2019-12-10
US20170305993A1 (en) 2017-10-26
US20180258155A1 (en) 2018-09-13
US11407807B2 (en) 2022-08-09
BR112017017289A2 (pt) 2018-04-10
US10155801B1 (en) 2018-12-18
AU2021204080A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
SG10202001485UA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
IL259304A (en) New peptides and a combination of peptides for use in immunotherapy against cll and other types of cancer
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201604458D0 (en) Peptides and combination of peptides for use in immunotherapy against cancers
SG10202110292UA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
IL257331A (en) New peptides and combinations of peptides for use in immunotherapy against prostate cancer and other types of cancer
IL256189A (en) New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
IL258599A (en) New peptides and a combination of peptides used in immunotherapy against breast cancer and other types of cancer
SG11201706155XA (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG10202001665QA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
ZA201707810B (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
GB201522667D0 (en) Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604490D0 (en) Peptides combination of peptides for use in immunotherapy against cancers
IL254129A0 (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
IL258609A (en) New peptides and a combination of peptides for use in immunotherapy against several types of cancer
IL254081B (en) New peptides and a combination of peptides for immunotherapeutic use against pancreatic cancer and other types of cancer
ZA201805512B (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
SG10202110335PA (en) Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
AT Applications terminated before publication under section 16(1)